These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 6177458)

  • 21. Abnormal macrophages and NK cell cytotoxicity in human systemic lupus erythematosus and the role of interferon and serum factors.
    Zippel D; Lackovic V; Kocisková D; Rovenský J; Borecký L; Stelzner A
    Acta Virol; 1989 Sep; 33(5):447-53. PubMed ID: 2483602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of interferon-alpha 2 and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome.
    Reddy MM; Chinoy P; Grieco MH
    J Biol Response Mod; 1984 Aug; 3(4):379-86. PubMed ID: 6332880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy.
    Pongnikorn S; Fongmoon D; Kasinrerk W; Limtrakul PN
    J Med Assoc Thai; 2003 Jan; 86(1):61-8. PubMed ID: 12678140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.
    Brunda MJ; Rosenbaum D
    Cancer Res; 1984 Feb; 44(2):597-601. PubMed ID: 6692364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS; Brandt CP; Tso CY; Laszlo J
    J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients.
    Balch CM; Tilden AB; Dougherty PA; Cloud GA; Abo T
    Surgery; 1984 Jan; 95(1):63-70. PubMed ID: 6581546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target-effector interactions in the rat NK cell system. II. Effects of interferon on lytic efficiency and on pre-NK cells in various organs, rat strains and during ontogeny.
    Flexman JP; Shellam GR
    Clin Exp Immunol; 1984 Jan; 55(1):229-38. PubMed ID: 6198116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity.
    Golub SH; D'Amore P; Rainey M
    J Natl Cancer Inst; 1982 May; 68(5):711-7. PubMed ID: 6175788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basic and interferon-augmented natural killer (NK) cell activity in psoriasis.
    Jansén CT; Viander M
    Acta Derm Venereol; 1983; 63(5):384-7. PubMed ID: 6197835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of human natural killer cell function by L-leucine methyl ester: monocyte-dependent depletion from human peripheral blood mononuclear cells.
    Thiele DL; Lipsky PE
    J Immunol; 1985 Feb; 134(2):786-93. PubMed ID: 3965574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the mechanism of natural killer cytotoxicity. III. Activation of NK cells by interferon augments the lytic activity of released natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2960-4. PubMed ID: 6189908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of suppressor cells for natural killer activity in cancer patients after surgery.
    Uchida A; Kolb R; Micksche M
    J Natl Cancer Inst; 1982 May; 68(5):735-41. PubMed ID: 6461792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.
    Pedersen BK; Oxholm P; Manthorpe R; Andersen V
    Clin Exp Immunol; 1986 Jan; 63(1):1-7. PubMed ID: 3485480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes.
    Nair MP; Schwartz SA
    J Immunol; 1984 Jun; 132(6):2876-82. PubMed ID: 6202765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen.
    Ziegler-Heitbrock HW; Fütterer A; Rumpold H; Kraft D; Munker R; Riethmüller G
    Clin Exp Immunol; 1984 Nov; 58(2):470-7. PubMed ID: 6333947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.